

CURRICULUM VITAE**INFORMAZIONI PERSONALI**

Nome	Massella Maurizio
Data di nascita	05/06/1969
Qualifica	Dirigente Professioni Sanitarie
Amministrazione	AGENZIA ITALIANA DEL FARMACO – AIFA
Incarico attuale	Assessor Ufficio Sperimentazioni Cliniche
Numero telefonico dell'ufficio	06-59784777
E-mail istituzionale	m.massella@aifa.gov.it

TITOLI DI STUDIO E PROFESSIONALI ED ESPERIENZE LAVORATIVE

Titolo di studio	Laurea in Farmacia
Altri titoli di studio e professionali	Master in Farmacoeconomia
Esperienze professionali (incarichi ricoperti)	Ricercatore di ruolo Istituto Superiore Sanità (1998-2017)
Capacità linguistiche	Buona conoscenza della lingua inglese scritta e parlata
Capacità nell'uso delle tecnologie	Ottima conoscenza pacchetto Office
Altro (partecipazione a convegni e seminari, pubblicazioni, collaborazione a riviste, ecc., ed ogni altra informazione che il dirigente ritiene di dover pubblicare)	Pubblicazioni

Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.

Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H, Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L, Wittkop L, Calvez V, Marcelin AG, Raffi F; **NEAT 001/ANRS 143 Study Group**. J Antimicrob Chemother. 2016 Apr;71(4)

Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy.

Winston A, Stöhr W, Antinori A, Arenas-Pinto A, Llibre JM, Amieva H, Cabié A, Williams I, Di Perri G, Tellez MJ, Rockstroh J, Babiker A, Pozniak A, Raffi F, Richert L; **NEAT 001/Agence Nationale de Recherche sur le SIDA (ANRS) 143 Study Group**.

HIV Med. 2016 Jun;17(6):471-8

Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. Bernardino JI, Mocroft A, Mallon PW, Wallet C, Gerstoft J, Russell C, Reiss P, Katlama C, De Wit S, Richert L, Babiker A, Buño A, Castagna A, Girard PM, Chene G, Raffi F, Arribas JR; **NEAT001/ANRS143 Study Group**. Lancet HIV. 2015 Nov;2(11)

L. Kondili, MG Quaranta, L.Falzano, A. Mallano, M.Mirra, LE Weimer, L.Fucili, M. Di Gregorio, S. Lucattini, **M. Massella**, R. Terlizzi, E. Olivieri, F. Magnani, A. Mattei, S. Rosato, ME Tosti, S. Vella and PITER Collaborating group PITER-HCV cohort study as a part of the italian platform for the study of viral hepatitis therapies Rapporti ISTISAN 15/35

Lambert-Niclot S, George EC, Pozniak A, White E, Schwimmer C, Jessen H, Johnson M, Dunn D, Perno CF, Clotet B, Plettenberg A, Blaxhult A, Palmisano L, Wittkop L, Calvez V, Marcelin AG, Raffi F; **NEAT 001/ANRS 143 Study Group**. Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. *J Antimicrob Chemother*. 2015 Dec 24.

Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A; **NEAT001/ANRS143 Study Group**. Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial *Lancet*. 2014 Nov 29;384(9958):1942-51

Winston A, Stöhr W, Antinori A, Arenas-Pinto A, Llibre JM, Amieva H, Cabié A, Williams I, Di Perri G, Tellez MJ, Rockstroh J, Babiker A, Pozniak A, Raffi F, Richert L Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. ; **NEAT 001/ANRS 143 Study Group** *HIV Med*. 2015 Nov 26

Sustained increase of serum creatine phosphokinase levels and progressive muscle abnormalities associated with raltegravir use during 32-week follow-up in an HIV-1 experienced patient on simplified HAART regimen, intolerant to protease inhibitors and abacavir: a case report . Cirioni O, Weimer LE, Fragola V, Giacometti A, Gabrielli E, Marchionni E, **Massella M**, Barchiesi F. *West Indian Med J*. 2013;62(4):377-9.

Weimer LE, Fragola V, Florida M, Guaraldi G, Ladisa N, Francisci D, Bellagamba R, Degli Antoni A, Parruti G, Giacometti A, Manconi PE, Vivarelli A, D'Ettorre G, Mura MS, Cicalini S, Preziosi R, Sighinolfi L, Verucchi G, Libertone R, Tavio M, Sarmati L, Bucciardini R; **ISS-NIA** Study Group.

Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection

J Antimicrob Chemother. 2013 Jan;68(1):193-9.

Bucciardini R, D'Ettorre G, Baroncelli S, Ceccarelli G, Parruti G, Weimer LE, Fragola V, Galluzzo CM, Pirillo MF, Lucattini S, Bellagamba R, Francisci D, Ladisa N, Degli Antoni A, Guaraldi G, Manconi PE, Vullo V, Preziosi R, Cirioni O, Verucchi G, Florida M; **ISS-NIA** study group.

Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors. Int J STD AIDS. 2012 Jul;23(7):459-63.

Massella M, Ivanovic J, Bellagamba R, De Vita R, Fracasso L, Tozzi V, Fragola V, Rizzica M, Narciso P. Cost of surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy. Patient Prefer Adherence. 2011;5:223-8.

Narciso P, Bucciardini R, Tozzi V, Bellagamba R, Ivanovic J, Giulianelli M, Scevola S, Palummieri A, Fragola V, **Massella M**, Fracasso L, De Vita R, Pierro P, Del Maestro A, Mirra M, Weimer L. Immediate versus delayed surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy: a randomized open-label study AIDS Res Hum Retroviruses.

Bucciardini R. **Massella M**, Corpolongo A, Narciso P, Fragola V, Mirra M, Donnini S, Viganò O, Costarelli S, Tozzi V T20QOL: an observational multicenter cohort study to evaluate the quality of life in HIV patients treated with enfuvirtide (ENF, T-20) in combination with an optimized background therapy. Biologics: Targets & Therapy 2008;2(3) 1-5.

Bucciardini R, Fragola V, **Massella M**, Polizzi C, Mirra M, Goodall R, Carey D, Hudson F, Zajdenverg R, Florida M; Initio Trial International Coordinating Committee. Health-related quality of life outcomes in HIV-infected patients starting different combination regimens in a randomized multinational trial: the INITIO-QoL substudy. *AIDS Res Hum Retroviruses*. 2007 Oct;23(10):1215-22.

Massella M, Bucciardini R, Fragola V "Qualità della Vita" del paziente: Outcome per una migliore valutazione di strategie terapeutiche. *Notiziario ISS* 2006, Volume 19, Numero 4

Bucciardini R, Murri R, Guarinieri M, Starace F, Martini M, Vatrella A, Cafaro L, Fantoni M, Grisetti R, Monforte A, Fragola V, Arcieri R, Del Borgo C, Tramarin A, **Massella M**, Lorenzetti D, Vella S. ISSQoL: a new questionnaire for evaluating the quality of life of people living with HIV in the HAART era. *Qual Life Res*. 2006 Apr;15(3):377-90.

Rezza G, Scalia Tomba G, Martucci P, **Massella M**, Noto R, De Risio A, Brunetti B, Ardita S, Starnini G Prevalence of the use of old and new drugs among new entrants in Italian prisons. *Ann Ist Super Sanita*. 2005;41(2):239-45.

Massella M, Arcieri R. Dall' AZT all' HAART

Positiviti-Infezioni da HIV: Repertorio delle sperimentazioni terapeutiche

Edizione 2003 Anno 9°

Florida M, Giuliano M, Germinario EAP, **Massella M**, Binelli A, Amici R. Gli antiretrovirali in gravidanza. *Giornale Italiano delle Malattie Infettive* Volume 7 Supplemento n. 2- 2001

Bucciardini R, Wu A. W, Floridia M, Fragola V, Ricciardulli D, Tomino C, Weimer L.E, Pirillo M. F, Mirra M, Marzi M, Giannini G, Galluzzo C. M, Andreotti M, **Massella M** and Vella S. Quality of life in a randomised clinical trial of zidovudine plus didanosine plus nevirapine or zidovudine plus didanosine for antiretroviral- naive patients with a clinical diagnosis of AIDS or CD4 counts below 200/mm³ (study ISS 047). AIDS. 2000 volume 14: 2567-2574

Hospitalizations and costs of treatment for protease inhibitor-based regimens in patients with very advanced HIV-infection (CD4 < 50/mm³).

Floridia M, **Massella M**, Bucciardini R, Perucci CA, Rossi L, Tomino C, Fragola V, Ricciardulli D, Galluzzo CM, Giannini G, Pirillo MF, Andreotti M, Mirra M, Vella S.

HIV Clin Trials. 2000 Sep-Oct;1(2):9-16.

The role of patient reported outcomes in the regulatory process needs to be better defined **PROmote*** group, Rome, Italy BMJ 4 February 2009

Enciclopedia Medica Italiana III Aggiornamento dell Seconda edizione: Inibitori dell'Entrata dell'HIV

A factor analytic study of the Italian National Institute of Health Quality of Life - Core Evaluation Form (ISSQoL-CEF). Lauriola M, Murri R, **Massella M**, Mirra M, Donnini S, Fragola V, Ivanovic J, Pavoni M, Mancini G, Bucciardini R.

Patient Prefer Adherence. 2010 Mar 24;4:33-44.

--	--